Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Short Interest Up 34.8% in November

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was the target of a large increase in short interest during the month of November. As of November 30th, there was short interest totalling 138,600 shares, an increase of 34.8% from the November 15th total of 102,800 shares. Based on an average daily volume of 4,269,100 shares, the short-interest ratio is currently 0.0 days.

Wall Street Analysts Forecast Growth

Separately, Bank of America upgraded Bayer Aktiengesellschaft from an “underperform” rating to a “neutral” rating in a research note on Friday, September 6th. One equities research analyst has rated the stock with a sell rating and five have issued a hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold”.

Bayer Aktiengesellschaft Stock Performance

Shares of OTCMKTS:BAYRY traded down $0.07 during trading hours on Friday, hitting $5.16. 896,226 shares of the company’s stock traded hands, compared to its average volume of 1,400,476. The company’s fifty day simple moving average is $6.16 and its two-hundred day simple moving average is $7.04. The company has a debt-to-equity ratio of 1.19, a quick ratio of 0.81 and a current ratio of 1.32. Bayer Aktiengesellschaft has a 52 week low of $4.94 and a 52 week high of $9.79.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last issued its earnings results on Tuesday, November 12th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.10). The business had revenue of $10.96 billion for the quarter. Bayer Aktiengesellschaft had a positive return on equity of 16.90% and a negative net margin of 2.02%. Research analysts forecast that Bayer Aktiengesellschaft will post 1.31 EPS for the current year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.